Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 527.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 84,682 shares of the company’s stock after acquiring an additional 71,182 shares during the quarter. International Assets Investment Management LLC’s holdings in Recursion Pharmaceuticals were worth $558,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in RXRX. ARK Investment Management LLC grew its position in Recursion Pharmaceuticals by 14.5% in the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after buying an additional 3,555,357 shares during the last quarter. Baillie Gifford & Co. boosted its stake in Recursion Pharmaceuticals by 10.5% in the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after purchasing an additional 2,522,132 shares during the period. Kinnevik AB publ boosted its stake in Recursion Pharmaceuticals by 14.4% in the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after purchasing an additional 1,500,000 shares during the period. Lingotto Investment Management LLP boosted its stake in Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock worth $27,563,000 after purchasing an additional 1,500,000 shares during the period. Finally, Ghisallo Capital Management LLC acquired a new position in Recursion Pharmaceuticals in the 2nd quarter worth approximately $8,250,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $6.82 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The firm’s 50-day moving average is $6.61 and its 200-day moving average is $7.64. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.03 and a 52-week high of $15.74. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -4.21 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. Recursion Pharmaceuticals’s revenue was up 30.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.38) earnings per share. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on RXRX shares. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.40.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total transaction of $76,923.84. Following the transaction, the director now directly owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,939,803.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the sale, the director now directly owns 7,077,560 shares of the company’s stock, valued at approximately $47,561,203.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 171,682 shares of company stock worth $1,107,868 over the last ninety days. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.